Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Maintains Buy on Ikena Oncology, Lowers Price Target to $11

Author: Benzinga Newsdesk | November 09, 2023 06:53pm
HC Wainwright & Co. analyst Andres Maldonado maintains Ikena Oncology (NASDAQ:IKNA) with a Buy and lowers the price target from $18 to $11.

Posted In: IKNA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist